



JPW

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/551,004	
	Filing Date	September 26, 2005	
	First Named Inventor	Henning Walczak	
	Group Art Unit	1644	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	4 + Refs.	Attorney Docket Number	045278-002000

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement with PTO-1449 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References (16)
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Birgit Millauer – Reg. No. 43,341 Nixon Peabody LLP 401 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	August 10, 2007

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (571) 273-8300	
August 10, 2007 Date	 Signature Helen A. Jackson



Application No. 10/551,004
Attorney Docket No. : 045278-002000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:) Confirmation No.: 1454
Henning Walczak) Examiner: Unassigned
Application No.: 10/551,004) Group Art Unit: 1644
Filed: September 26, 2005) Customer No.: 22204
For: IMPROVED FC FUSION PROTEINS)

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office via first class mail on 8-10-07.

Signature: Helen A. Jackson

NIXON PEABODY LLP

Name: Helen A. Jackson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form and return it to the undersigned

The Commissioner is hereby authorized to charge any fees connected with this Information Disclosure Statement which may be required now, or credit any overpayment, to Deposit Account No. 50-3557.

Respectfully submitted,



Birgit Millauer
Registration No. 43,341

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
Telephone: (202) 585-8000



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/551,004
				Filing Date	September 26, 2005
				First Named Inventor	Henning Walczak
				Art Unit	1644
				Examiner Name	Unassigned
				Attorney Docket Number	045278-002000
Sheet	1	of	B1	1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)			
	A1	US-6,015,559	01/18/2000	Lynch, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ²	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	B1	WO	02/090553	11/14/2002	Erfinder, et al.		
	B2	WO	02/079415	10/10/2002	Gillies		
	B3	WO	02/066514	08/29/2002	Gillies, et al.		
	B4	WO	01/49866	07/12/2001	Erfinder, et al.		
	B5	WO	01/41803 A1	06/14/2001	Erfinder, et al.		
	B6	EP	0 992 243	04/12/2000	Nagata, et al.		
	B7	WO	00/18932	04/06/2000	Stahl, et al.		
	B8	EP	0 965 637	12/22/1999	Nakamura, et al.		
	B9	WO	99/50413	10/07/1999	Bumol, et al.		
	B10	WO	98/36768	08/27/1998	Grooten, et al.		
	B11	WO	95/27735	10/19/1995	Krammer, et al.		
	B12	EP	0 526 452	02/10/1993	Capon, et al.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	DEMJEN, D <i>et al.</i> , "Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury", <i>Nat. Med</i> 10(4):389-395, 2004.	
	C2	KIM, Yon Su <i>et al.</i> , "Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc 2a Protein Blocks Delayed-Type Hypersensitivity", <i>J. Immunol</i> 160:5742-5748, 1998.	
	C3	MARTIN-VILLALBA, A. <i>et al.</i> , "Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke", <i>Cell Death Differ.</i> 8(7):679-686, 2001.	
	C4	SMITH, CA <i>et al.</i> , "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family cytokines with homology to TNF", <i>Cell</i> 73(7):1349-1360, 1993	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.